B+
Bull case
20%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
SGMT
Sagimet BiosciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
FDA clearance, identified AURORA sites and the stated Q4 enrollment plan make the U.S. acne program more tangible.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
AURORA screening or enrollment could slip beyond the stated Q4 2026 plan; the trial still must establish efficacy and long-term safety in U.S. patients [#PR-2026-08-25].
Momentum
60
Value
41
Sentiment
40
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.00 · Bull $15.00 · Bear $4.50Analysis 2026-09-25; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $27.92
Why
Momentum60 · Δ7d +17.7
Value41 · Δ7d -0.1
Sentiment40 · Δ7d -16.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • AURORA screening or enrollment could slip beyond the stated Q4 2026 plan; the trial still must establish efficacy and long-term safety in U.S. patients [#PR-2026-08-25].
- • Q2 research-and-development expense rose to $11.5 million from $7.2 million a year earlier; Phase 3 spending could challenge management's through-2028 runway estimate [#SEC-8K-2026-08-11].
- • Enrollment has not been confirmed in the checked sources, and a trial start is not evidence of U.S.
Catalyst clock
2026-12-31
AURORA Phase 3 patient enrollment
Lead driver: Value · See fundamentals
Momentum
60
8% active weight
Current posture
7d trendImproving
Δ7d
+17.7
Δ21d
-21.4
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
40
45% active weight
Current posture
7d trendSoftening
Δ7d
-16.7
Δ21d
-11.7
Why this grade
Composite grade D. Momentum 59.8 / Value 40.6 / Sentiment 39.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-25. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$673.87M
Beta
-
Shares Out
70.91M
P/E (TTM) · Derived
-6.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-8.26
Rev YoY
-100.0%
EPS YoY
-18.6%
Gross Margin
+98.3%
Op Margin
-1813.8%
Net Debt
-$113.05M
Current Ratio
44.94
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data